Wave Life Sciences
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
96% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 24
95% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 38
73% more call options, than puts
Call options by funds: $9.23M | Put options by funds: $5.33M
61% more capital invested
Capital invested by funds: $989M [Q3] → $1.59B (+$602M) [Q4]
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
13% more funds holding
Funds holding: 160 [Q3] → 181 (+21) [Q4]
9.84% less ownership
Funds ownership: 94.17% [Q3] → 84.33% (-9.84%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
184%
upside
Avg. target
$24
210%
upside
High target
$26
236%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 357 met price target | 184%upside $22 | Buy Reiterated | 26 Mar 2025 |
Jefferies Roger Song 24% 1-year accuracy 4 / 17 met price target | 236%upside $26 | Buy Initiated | 25 Feb 2025 |
Financial journalist opinion
Based on 7 articles about WVE published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

Positive
Seeking Alpha
5 days ago
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dystrophy market, in the 7 major markets, will reach $5.2 billion by 2033.

Positive
Zacks Investment Research
5 days ago
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Positive
Benzinga
6 days ago
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
Wave Life Sciences Ltd. WVE released data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon-skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Neutral
GlobeNewsWire
6 days ago
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA

Neutral
Seeking Alpha
4 weeks ago
Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Kate Rausch - VP, IR & Corporate Affairs Paul Bolno - President & CEO Erik Ingelsson - Chief Scientific Officer Kyle Moran - Chief Financial Officer Conference Call Participants Ron Feiner - JPMorgan Salim Syed - Mizuho Joon Lee - Truist Securities Joe Schwartz - Leerink Partners Roger Song - Jefferies Catherine Novack - Jones Trading Ryan Deschner - Raymond James Madison El-Saadi - B.

Neutral
GlobeNewsWire
4 weeks ago
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort

Neutral
GlobeNewsWire
1 month ago
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company's fourth quarter and full year 2024 financial results and provide business updates.

Neutral
GlobeNewsWire
1 month ago
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)

Positive
Seeking Alpha
2 months ago
Wave Life Sciences Is A Buy On Pipeline Prospects
Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–10 quarters, though approval for its programs is still years away.

Charts implemented using Lightweight Charts™